Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nectin4/FAP-targeted 4th-gen CAR-T in advanced solid tumors
NCT03932565Phase 1Unknown
- Sponsor
- Lishui People's Hospital
- Start
- Feb 2019
- Primary completion
- Jun 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Nectin4/FAP-targeted fourth-generation CAR-T cells in solid tumor, sponsored by Lishui People's Hospital. Primary endpoint: Adverse events related to treatment at 2 years. Status: unknown.
02
Drugs
Nectin4/FAP-targeted fourth-generation CAR-T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03932565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932565.